Results 191 to 200 of about 138,877 (380)

Haemorrhagic conjunctivitis with pseudomembranous related to SARS-CoV-2

open access: yesAmerican Journal of Ophthalmology Case Reports, 2020
V. Navel, F. Chiambaretta, F. Dutheil
semanticscholar   +1 more source

Gonorrhea Management in High‐, Limited‐ and No‐Resource Settings: Implications in the Context of Antimicrobial Resistance

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Gonorrhea, a common sexually transmitted infection caused by Neisseria gonorrhoeae, represents an escalating global public health threat due to antimicrobial resistance. The current review explores diverse approaches around the globe to gonorrhea management across various settings, with a focus on diagnostic strategies, treatment practices ...
Andrei Tanasov   +2 more
wiley   +1 more source

Efficacy and Safety of Anti‐IL‐4Rα Stapokibart in Elderly Patients With Moderate‐To‐Severe Atopic Dermatitis

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Background Elderly patients with moderate‐to‐severe atopic dermatitis (AD) often exhibit more heterogeneous inflammatory profiles compared with younger adults. To evaluate the efficacy and safety of stapokibart, an anti‐interleukin‐4 receptor α subunit (IL‐4Rα) monoclonal antibody, in different age subgroups.
Yan Zhao   +26 more
wiley   +1 more source

Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta‐Analysis

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Prurigo nodularis (PN) is a chronic, intensely pruritic skin disorder characterized by hyperkeratotic nodules and a debilitating itch–scratch cycle. Conventional therapies have limited efficacy and safety issues, while biologics have recently emerged as a promising alternative.
Andrea Lancz   +7 more
wiley   +1 more source

Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo   +11 more
wiley   +1 more source

Patch Testing Under Biologics: Six Cases From a Tertiary Centre

open access: yes
Contact Dermatitis, EarlyView.
Alessandra Chiei‐Gallo   +3 more
wiley   +1 more source

A Qualitative Study Exploring Nursing Scope of Practice for the Care of People Experiencing Homelessness

open access: yesJournal of Advanced Nursing, EarlyView.
ABSTRACT Aim To explore the key knowledge, skills, attributes and organisational support that nurses require to optimise their scope of practice when providing care to people experiencing homelessness. Design A qualitative descriptive study exploring nurses' scope of practice for addressing health needs of people experiencing homelessness.
Olivia Hollingdrake   +4 more
wiley   +1 more source

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin   +24 more
wiley   +1 more source

Home - About - Disclaimer - Privacy